1. Impact of endoscopic ultrasound-guided fine-needle aspiration in prospective liver transplant recipients with hepatocellular carcinoma and lymphadenopathy
- Author
-
Haimanti Sarin, Mukesh Nasa, Arvinder S. Soin, Narendra S. Choudhary, Prashant Bhangui, Randhir Sud, Rajesh Puri, Neeraj Saraf, Mridula Guleria, Vinit Shah, and Sanjiv Saigal
- Subjects
Male ,Endoscopic ultrasound ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cirrhosis ,Mediastinal lymphadenopathy ,medicine.medical_treatment ,Lymphadenopathy ,Liver transplantation ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,medicine ,Humans ,Prospective Studies ,Endoscopic Ultrasound-Guided Fine Needle Aspiration ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,Gastroenterology ,Middle Aged ,medicine.disease ,digestive system diseases ,Liver Transplantation ,Transplantation ,surgical procedures, operative ,Fine-needle aspiration ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Female ,030211 gastroenterology & hepatology ,Radiology ,business - Abstract
Diagnosis of metastatic disease is important in patients with cirrhosis and hepatocellular carcinoma (HCC) to prevent futile liver transplantation. Some of these patients have metastatic lymphadenopathy; however, it is difficult to perform percutaneous fine-needle aspiration due to presence of collateral and anatomic location. Endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) of lymph nodes offers several advantages like real-time vision, proximity to target, and avoidance of collaterals. The aim of this study was to look for metastatic lymphadenopathy by EUS-guided FNA (EUS-FNA) in prospective liver transplant recipients with HCC. A prospective study was conducted from January 2013 to January 2016 at a tertiary care center. All prospective liver transplant recipients with HCC had PET-CT and bone scan to look for metastatic disease. EUS-FNA was done in patients with abdominal or mediastinal lymphadenopathy and no evidence of extrahepatic disease. Data is shown as median (25–75 interquartile range). EUS-guided FNA was done for 50 patients (42 abdominal and 8 mediastinal lymph nodes), age 57 (53–62) years, Child-Turcotte-Pugh 7 (6–9), and model for end-stage liver disease 10 (7–16). FNA material was adequate in 92% patients, metastasis in 15 (30%), granulomatous lymphadenopathy in 4 (8%), and reactive change in 27 patients (54%). The material was inadequate for diagnosis in 4 (8%) patients. Thus, EUS-guided FNA precluded transplantation in 30% of patients with lymphadenopathy, and 4 (8%) patients received anti-tubercular therapy before liver transplantation. In patients with HCC and lymphadenopathy, EUS-guided FNA detected metastatic disease and precluded liver transplantation in approximately one third of patients.
- Published
- 2016
- Full Text
- View/download PDF